Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 16/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9887047 | 0.85 | BRD4 (0.49) | BRD4CYP1A2HSD17B10 | |
| SCHEMBL16705453 | 0.82 | BRD4 (0.44) | BRD4CYP1A2HSD17B10 | |
| SCHEMBL9886993 | 0.82 | CYP1A2 (0.46) | BRD4CYP1A2HSD17B10 | |
| SCHEMBL9974004 | 0.82 | BRD4 (0.42) | BRD4 | |
| SCHEMBL9932378 | 0.79 | BRD4 (0.56) | BRD4CYP1A2HSD17B10 | |
| SCHEMBL9282881 | 0.77 | BRD4 (0.41) | BRD4 | |
| SCHEMBL16694845 | 0.74 | BRD4 (0.43) | BRD4 | |
| SCHEMBL9974036 | 0.69 | BRD4 (0.50) | BRD4 | |
| SCHEMBL19574893 | 0.68 | CYP1A2 (0.60) | CYP1A2DRD4HSD17B10 | |
| SCHEMBL13684801 | 0.68 | CYP1A2 (0.60) | CYP1A2DRD4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522920-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-12-20 | — | — | US | disclosed |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8796261-B2 | Bromodomain inhibitors and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157428-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885CYP1A2 4557/4885DRD4 4333/4885 |
| US-20140371206-A1 | BROMODOMAIN INHIBITORS AND USES THEREOF | BRD4, BRPF3, BRDT | BRD4 1/4885CYP1A2 4557/4885DRD4 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.